Psilocybin and Treatment Resistant Depression Study

PSILOCYBIN AND TREATMENT RESISTANT DEPRESSION STUDY

Many people who receive antidepressant treatment for their depression do not get an adequate response to the medicines they are taking. If someone is taking two or more antidepressants and they are failing, this is sometimes referred to as treatment-resistant depression or TRD.

The COMP 006 study is looking into a new treatment approach for people with TRD using an investigational medicine given with psychological support. The study is suitable for people who have been diagnosed with major depression and are currently experiencing a recurrent or single episode of depression but that have not
responded to antidepressant treatment.

You may eligible to participate in a Compass Pathfinder study if you:

  • Are 18 years of age or older
  • Have been diagnosed with major depression (single or recurrent episodes)
  • Are experiencing treatment-resistant depression, defined as failing 2, 3 or 4 pharmacological treatments for your current episode of depression
  • Meet additional study criteria

About the study:

COMP006 is a three-part study which will last up to 62 weeks.

Participants will receive support from study clinicians to help them withdraw off any prohibited medications, including current antidepressants. Participants will be asked to remain off prohibited medications for parts of the study under close medical supervision.

Reimbursement for reasonable, out-of-pocket expenses for travel and other expenses may be available to qualified individuals.

Find out more:

If you are interested in learning more about the COMP006 study, please complete the pre-screen questionnaire below.

Site Principal Investigator (Study Doctor):

 

Dr. Shimi Kang, MD, FRCPC

Receive up to $150 through our refer-a-friend program!